Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
52W High
$2.79
52W Low
$1.50
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.69
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.52
EV/Revenue (<3 favorable)
502.48
P/S (TTM) (<3 favorable)
566.67
P/B (<3 favorable)
5.45
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
24.31%
Institutions (25–75% balanced)
22.36%
Shares Outstanding
45,663,400
Float
28,765,600
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
166,000
Gross Profit (TTM)
0
EPS (TTM)
-0.26
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-63.79%
ROE (TTM) (>15% strong)
-0.82%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.92
Momentum
Bearish momentumValue
-0.0260
Previous
-0.0118
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025